Judgment of the National Green Tribunal in the matter of Shalbjit Singh Vs Punjab State Pollution Control Board & Others dated 21/11/2024. A letter petition dated November 5, 2022 was sent by Shalabhjeet Singh, resident of village Haibatpur, tehsil Derabassi, district SAS Nagar, Mohali complaining that M/s Nectar Life Sciences …
With demand for the antidote to H1N1 infection peaking across the world, the select Indian pharmaceutical companies are ramping up production of Tamiflu or its generic version. At least one such company, Hetero Drugs, is already in the process of supplying 1 million capsules to the Government of India and …
May be the first new chemical entity developed and marketed by an Indian company. Malvinder singhSix years after the Geneva-based, not-for-profit organisation, Medicines for Malaria Venture (MMV), made Ranbaxy its drug development partner, the latter today announced the start of final-stage clinical trials for a new anti-malaria drug. Ranbaxy expects …
New Delhi, May 4 Ranbaxy Laboratories Ltd on Monday announced the commencement of the third phase clinical trials for its new anti-malaria combination drug in India, Bangladesh and Thailand. The drug, Arterolane maleate + Piperaquine phosphate, is targeted at patients in developing countries with the aim of significantly improving upon …
PB Jayakumar / Mumbai May 2, 2009, 0:14 IST Tokyo's policy push for generics an added draw. Leading Indian drug makers such as Ranbaxy, Lupin, Zydus Cadila and Dishman, which forayed into Japan in the past three years, have emerged as important players in the generic or copycat drug business …
PAWAN BALI The spread of Swine flu is likely to boost the sales of companies like Cipla, which can provide drugs and vaccines for this deadly disease. Ms Sarabjit Kaur Nagra, pharma analyst with Angel Broking said that Cipla and Ranbaxy are the two Indian companies, which can provide drugs …
Joe C Mathew / New Delhi March 06, 2009, 0:37 IST Ranbaxy, facing data falsification charges from the United States Food and Drug Administration (USFDA) at one of its Indian facilities, has relied upon the drug making capabilities of its US subsidiary, Ohm Laboratories, to replenish its US product basket. …
Bloomberg / Mumbai September 26, 2008, 0:14 IST American relief programme suspends funding for three generic medicines. AIDS drugs made by Ranbaxy Laboratories won't be purchased under an American programme to supply medicines to developing countries after the US cited the company for violations in two of its plants. The …
D G Shah Secretary General IPA* A sense of doom is not at all warranted THE recent FDA action is a warning for several other companies that are already in the US market or intend to enter it in the near future. Just as they had learnt to emulate the …
Daiichi Sankyo has said that there are procedural delays in completing the open offer for acquiring an additional 20% equity of Ranbaxy. The delay pertains to payments to shareholders who have subscribed to the Japanese company's open offer for acquiring an additional 20% equity of Ranbaxy. Daiichi will pay interest …
THE U.S. BAN ON some medicines made by India's largest pharmaceutical company adds a black mark against India's booming drug and drug-testing industries, which already have been under pressure over the country's lax monitoring of drug safety. India's pharmaceutical industry was once the nemesis of U.S. drug companies, producing knock-off …
Lapses on record-keeping Affects numerous, widely-used medications Preventive action to protect quality of drugs WASHINGTON: U.S. health officials have blocked dozens of drugs made by Ranbaxy Laboratories after the generic drugmaker failed to fix numerous record-keeping and other operational problems, although the medications themselves are considered safe. The U.S. Food …
Joe C Mathew / New Delhi August 27, 2008, 0:39 IST Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US. Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. …
